​Most Harvard teaching hospitals will accept WHO vaccinated workers consistent with Melanie's description. 

  Tom Winters


From: MCOH-EH <mcoh-eh-bounces+twinters=bidmc.harvard.edu@mylist.net> on behalf of Swift, Melanie D., M.D., M.P.H. via MCOH-EH <mcoh-eh@mylist.net>
Sent: Tuesday, July 13, 2021 11:57 AM
To: MCOH-EH
Cc: Swift, Melanie D., M.D., M.P.H.
Subject: [External] Re: [MCOH-EH] Question about international COVID vaccines
 

Here’s the link to the WHO Emergency Use Listing: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02July2021.pdf

 

According to CDC if the vaccine has been added to the EUL (“finalized” on this document) then no further vaccination should be necessary. Note the following facets of this EUL:

  • The assessments of international vaccines will change over time. They just added Sinopharm/BIBP to this list in early May. Prior to that we would have told people who received Sinopharm that they should get one of the FDA EUA vaccines; but now we wouldn’t.
  • They are adding the individual manufacturer, not just a platform or brand. So for instance, AstraZeneca vaccine manufactured in Japan or Australia is not yet listed but that made in Europe or Korea is. The Sinopharm that is made by the Beijing Institute of Biological Products has completed the process and is on the list, but the one made by Wuhan Institute of Biological Products has not. Much like the FDA, it’s not just that the recipe/platform works, they are verifying the production standards and practices at the manufacturing facilities. This is really difficult because vaccination records do not get that specific.
  • The listing process may not always appear to make sense with clinical trial data. Sputnik V has not completed the listing process, but the vaccine had high efficacy in their phase 3 trial. Again, like the FDA process, they have to consider more than the clinical trial data, like the integrity of the manufacturing process, so there may be factors that we aren’t aware of that can hold up approval.

 

Melanie

 

Melanie Swift, MD, MPH

(she/her)
Practice Chair, Division of Preventive, Occupational, and Aerospace Medicine

Medical Director, Mayo Clinic Physician Health Center

Associate Medical Director, Occupational Health Service

Co-Chair, COVID Vaccine Allocation and Delivery

_______________________________
Mayo Clinic
200 First Street SW
Rochester, MN 55905

 

From: MCOH-EH <mcoh-eh-bounces@mylist.net> On Behalf Of Radke, Laura L. M.D.
Sent: Monday, July 12, 2021 5:33 PM
To: 'mcoh-eh@mylist.net' <mcoh-eh@mylist.net>
Subject: [EXTERNAL] [MCOH-EH] Question about international COVID vaccines

 

Our medical school has raised some questions about international COVID vaccines related to visiting researchers, housestaff, students and others who may have been immunized in a foreign country, now coming to the US to work/train/etc.  Curious to see how others may be handling the following situations:

 

  1. Do you have a list of foreign vaccines (not FDA-approved) which are felt to be acceptable for full COVID vaccination?
  2. Will you accept proof of vaccination from a foreign country?
  3. If so, what type of documentation is required?
  4. What if the documentation is in a foreign language?  English translation required?  By whom?

 

While COVID vaccine is currently not mandatory at our institutions, we are keeping track of who has been vaccinated in our EMR and feel this is likely to come up in the near future.

 

Thank you for your input!

 

Laura L Radke, MD

Adjunct Assistant Professor of Medicine

Medical Director, F&MCW Occupational Health Services

Phone: 262-253-8197 | Fax: 262-253-5152 Cell Phone: 414-530-0723

E-mail: laura.radke@froedtert.com

Froedtert & the Medical College of Wisconsin Workforce Health / North Hills Health Center Building B First Floor

W129 N7055 Northfield Dr.

Menomonee Falls, WI 53051

 


______________________________________________________________________
Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.
______________________________________________________________________




This message is intended for the use of the person(s) to whom it may be addressed. It may contain information that is privileged, confidential, or otherwise protected from disclosure under applicable law. If you are not the intended recipient, any dissemination, distribution, copying, or use of this information is prohibited. If you have received this message in error, please permanently delete it and immediately notify the sender. Thank you.